You are here:

MS in the media - 4 March 2016

Published on

27 February - 4 March 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.

Recommendations for Tysabri and PML

The European Medicines Agency (EMA) has confirmed its recommendation on closer monitoring of people on Tysabri at risk of the brain infection PML.  People who are JC virus positive, have been on Tysabri for two years or more and been on immunosuppressant drugs should only continue treatment "if benefits outweigh the risks".

Source: EMA

MS Trust link: Tysabri (natalizumab)

Neurological services in Scotland

A Sue Ryder campaign highlights the gaps in provision in neurological services in Scotland, particularly the number of younger people in care homes for older people.

Source:The Scotsman
Source: Sue Ryder

MS Trust link: Young people with MS being cared for in older people’s care homes

Pregnancy and risk of progression

Italian research studied mothers with MS - one group who had had one pregnancy and another who had more than one.  There was no difference between groups in disability measures over seven years, suggesting having multiple pregnancies doesn't after progression

Source: MS News Today

MS Trust link: Pregnancy

Virtual reality and balance

Israeli research compared sessions in a virtual reality device with standard exercise over six weeks.  Both methods improved balance but the virtual reality group improve more.

Source: BioMed Central

MS Trust link: Balance

Rituximab trial unsuccessful for SPMS

A small trial of rituximab in secondary progressive MS has ended early as interim results showed it was unlikely to be effective.  The drug is similar to ocrelizumab, which has shown potential effectiveness 

Source: National MS Society (USA)

MS Trust link: Ocrelizumab

Coffee and risk of MS

Swedish/US research looked at medical records and found that people who drank coffee had a lower risk of developing MS than those who did not.

Source: Daily Telegraph
Source: Independent
Source: Medical News Today

MS Trust link: Research updates

Print this page